At the double: leading vape technology brand FEELM shows off two latest advancements in Dubai
FEELM – part of leading atomization technology company SMOORE – exhibited two game-changing innovations, which have been developed to ‘raise product performance’ across the disposable vape category, during a major industry event in the Middle East.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230621395128/en/
(Photo: Business Wire)
Presented at this year’s World Vape Show in Dubai, the brand’s FEELM Max’s ceramic coil and TOPOWER battery technology were created as part of a targeted effort to ‘level up the single-use sector’ and enhance consumer experience.
The pioneering advancements both earned attention from the industry and are already appearing in devices from globally recognised brands. FEELM says each was designed to address a ‘pain point’ of the industry.
FEELM pioneers the disposable sector with two breakthroughs
In the UK, the capacity of vapes should meet the requirement of 2 ml according to TPD directive act. FEELM, as a responsible brand always compliant with laws and regulations, rolls out a groundbreaking technology with which 2 ml disposables showcase higher product performance.
FEELM Max’s ceramic coil has done away with super-absorbent cotton to reduce the amount of e-liquid that goes to waste and increase the puff count of TRPR and TPD compliant 2ml disposables in the UK by as much as 30% - a rise from 600 to at least 800 puffs. Thanks to this innovation, consumers can have an unprecedentedly better vaping experience while using compliant products.
It also reduces impurities by 78% during the heating process, produces air particles that are 55% smaller than mainstream solutions and uses a ‘constant power engine’ that provides a vapour consistency of 95% and a 35% improvement in taste consistency.
The second notable innovation is FEELM’s TOPOWER battery technology. This breakthrough increases the endurance of large e-liquid capacity vapes and can provide over 6,000 puffs without needing to recharge, which allows consumers to get rid of the hassle of charging.
Further, the compact power solution – which offers 30% more capacity – delivers a consistent output which FEELM says will counter the common issue of flavour reduction caused by voltage drop.
TOPOWER also promises a longer shelf life, with 1% power attenuation over six months and 3% power attenuation over a year. This advancement effectively avoids the burn taste and assures a strong consistency of taste, which means every puff consumers take is pleasant.
Speaking on the developments, Rex Zhang, the Assistant President at FEELM, said: “We pride ourselves on being the brand behind the brands and believe our technology has become to vaping what Intel Core processors are to laptops. We aim to elevate the disposable category to a whole new level through innovation– our ceramic coils and TOPOWER battery solution represent two significant successes on this front.”
Rex added that technology will be a ‘critical metric’ on which to measure the winners and losers of the industry moving forward. He said: “The vape category is fuelled by the desire to help adult smokers switch away from cigarettes – but it is built on innovation.”
FEELM Max’s commercialization and admiration from European customers
FEELM Max has helped customers boost business success and earned high praise at the World Vape Show Dubai expo, with some leading brands commenting on the new developments.
Since the launch of HEXA GO with FEELM Max solution in 2022, the sales of HEXA have steadily increased and HEXA GO has become dominant in the Belgian disposable market. Consumers generally give positive feedback on their products’ ‘smooth taste’, ‘strong consistency’, and ‘higher puff counts’.
Mattia Sparacino, CEO and founder of KIWI Vapor, said of the FEELM Max ceramic coil: “It’s an amazing technology and I hope it will be accessible to all people one day.”
Commenting on the need for advancement in the vape category, John Dunne of the UK Vaping Industry Association said: “Our sector has made significant progress since the first devices hit the market and provided adult smokers with a less harmful alternative to cigarettes.
“We must continue to capitalise on the innovative spirit of our community and invest in new and exciting technologies that can help on the journey to a smoke-free future.”
About FEELM
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE
Founded in 2009, SMOORE is a global leader in atomization technology solutions, covering reduced-risk products, medical, pharmaceutical, and beauty atomization technologies. With inter-disciplinary atomization research and a diverse product portfolio, SMOORE is committed to becoming an advanced platform, aspired to make life better.
With continuous R&D investment and leading manufacturing capacity, SMOORE has 14 technology research centers worldwide and products are available in more than 50 countries and regions. SMOORE announced IPO in Hong Kong on July 10, 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230621395128/en/
Contact information
Claudia Liu
86 13974468623
mengmeng.liu@smooretech.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
